These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 16740688

  • 1. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.
    Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G, Milella M.
    Cancer Res; 2006 Jun 01; 66(11):5549-54. PubMed ID: 16740688
    [Abstract] [Full Text] [Related]

  • 2. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T.
    Clin Cancer Res; 2009 Mar 01; 15(5):1612-22. PubMed ID: 19223496
    [Abstract] [Full Text] [Related]

  • 3. AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells.
    Frost P, Shi Y, Hoang B, Lichtenstein A.
    Oncogene; 2007 Apr 05; 26(16):2255-62. PubMed ID: 17016437
    [Abstract] [Full Text] [Related]

  • 4. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.
    Klos KS, Wyszomierski SL, Sun M, Tan M, Zhou X, Li P, Yang W, Yin G, Hittelman WN, Yu D.
    Cancer Res; 2006 Feb 15; 66(4):2028-37. PubMed ID: 16489002
    [Abstract] [Full Text] [Related]

  • 5. Rhein inhibits angiogenesis and the viability of hormone-dependent and -independent cancer cells under normoxic or hypoxic conditions in vitro.
    Fernand VE, Losso JN, Truax RE, Villar EE, Bwambok DK, Fakayode SO, Lowry M, Warner IM.
    Chem Biol Interact; 2011 Jul 15; 192(3):220-32. PubMed ID: 21457705
    [Abstract] [Full Text] [Related]

  • 6. Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer.
    Liu M, Howes A, Lesperance J, Stallcup WB, Hauser CA, Kadoya K, Oshima RG, Abraham RT.
    Cancer Res; 2005 Jun 15; 65(12):5325-36. PubMed ID: 15958580
    [Abstract] [Full Text] [Related]

  • 7. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling.
    Wang Y, Zhao Q, Ma S, Yang F, Gong Y, Ke C.
    IUBMB Life; 2007 Nov 15; 59(11):717-21. PubMed ID: 17968710
    [Abstract] [Full Text] [Related]

  • 8. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.
    Verheul HM, Salumbides B, Van Erp K, Hammers H, Qian DZ, Sanni T, Atadja P, Pili R.
    Clin Cancer Res; 2008 Jun 01; 14(11):3589-97. PubMed ID: 18519793
    [Abstract] [Full Text] [Related]

  • 9. Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma.
    Miyazawa M, Yasuda M, Fujita M, Kajiwara H, Hirabayashi K, Takekoshi S, Hirasawa T, Murakami M, Ogane N, Kiguchi K, Ishiwata I, Mikami M, Osamura RY.
    Pathol Int; 2009 Jan 01; 59(1):19-27. PubMed ID: 19121088
    [Abstract] [Full Text] [Related]

  • 10. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis.
    Shor B, Zhang WG, Toral-Barza L, Lucas J, Abraham RT, Gibbons JJ, Yu K.
    Cancer Res; 2008 Apr 15; 68(8):2934-43. PubMed ID: 18413763
    [Abstract] [Full Text] [Related]

  • 11. mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.
    Cejka D, Preusser M, Fuereder T, Sieghart W, Werzowa J, Strommer S, Wacheck V.
    Anticancer Res; 2008 Apr 15; 28(6A):3801-8. PubMed ID: 19189667
    [Abstract] [Full Text] [Related]

  • 12. A quassinoid 6alpha-tigloyloxychaparrinone inhibits hypoxia-inducible factor-1 pathway by inhibition of eukaryotic translation initiation factor 4E phosphorylation.
    Jin X, Jin HR, Lee D, Lee JH, Kim SK, Lee JJ.
    Eur J Pharmacol; 2008 Sep 11; 592(1-3):41-7. PubMed ID: 18639543
    [Abstract] [Full Text] [Related]

  • 13. The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models.
    Zhao H, Cui K, Nie F, Wang L, Brandl MB, Jin G, Li F, Mao Y, Xue Z, Rodriguez A, Chang J, Wong ST.
    Breast Cancer Res Treat; 2012 Jan 11; 131(2):425-36. PubMed ID: 21394501
    [Abstract] [Full Text] [Related]

  • 14. Noscapine inhibits hypoxia-mediated HIF-1alpha expression andangiogenesis in vitro: a novel function for an old drug.
    Newcomb EW, Lukyanov Y, Schnee T, Ali MA, Lan L, Zagzag D.
    Int J Oncol; 2006 May 11; 28(5):1121-30. PubMed ID: 16596228
    [Abstract] [Full Text] [Related]

  • 15. Anti-angiogenic effects of ribonucleic acid interference targeting vascular endothelial growth factor and hypoxia-inducible factor-1alpha.
    Forooghian F, Das B.
    Am J Ophthalmol; 2007 Nov 11; 144(5):761-8. PubMed ID: 17869204
    [Abstract] [Full Text] [Related]

  • 16. Targeting of mTOR is associated with decreased growth and decreased VEGF expression in acute myeloid leukaemia cells.
    Böhm A, Aichberger KJ, Mayerhofer M, Herrmann H, Florian S, Krauth MT, Derdak S, Samorapoompichit P, Sonneck K, Vales A, Gleixner KV, Pickl WF, Sperr WR, Valent P.
    Eur J Clin Invest; 2009 May 11; 39(5):395-405. PubMed ID: 19320940
    [Abstract] [Full Text] [Related]

  • 17. Nitric oxide in physiologic concentrations targets the translational machinery to increase the proliferation of human breast cancer cells: involvement of mammalian target of rapamycin/eIF4E pathway.
    Pervin S, Singh R, Hernandez E, Wu G, Chaudhuri G.
    Cancer Res; 2007 Jan 01; 67(1):289-99. PubMed ID: 17210710
    [Abstract] [Full Text] [Related]

  • 18. In vitro and in vivo anti-angiogenic activities and inhibition of hormone-dependent and -independent breast cancer cells by ceramide methylaminoethylphosphonate.
    Chintalapati M, Truax R, Stout R, Portier R, Losso JN.
    J Agric Food Chem; 2009 Jun 24; 57(12):5201-10. PubMed ID: 19476359
    [Abstract] [Full Text] [Related]

  • 19. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
    Chang SB, Miron P, Miron A, Iglehart JD.
    J Surg Res; 2007 Mar 24; 138(1):37-44. PubMed ID: 17109887
    [Abstract] [Full Text] [Related]

  • 20. Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro.
    Weigand M, Hantel P, Kreienberg R, Waltenberger J.
    Angiogenesis; 2005 Mar 24; 8(3):197-204. PubMed ID: 16328160
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.